WINTON GROUP Ltd Has $2.84 Million Stock Position in Bio-Techne Corp $TECH

WINTON GROUP Ltd reduced its holdings in shares of Bio-Techne Corp (NASDAQ:TECH) by 57.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 51,100 shares of the biotechnology company’s stock after selling 69,994 shares during the period. WINTON GROUP Ltd’s holdings in Bio-Techne were worth $2,843,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Goldman Sachs Group Inc. boosted its holdings in shares of Bio-Techne by 12.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock valued at $62,379,000 after acquiring an additional 113,634 shares in the last quarter. Woodline Partners LP increased its holdings in Bio-Techne by 40.0% in the 1st quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 3,814 shares in the last quarter. Assetmark Inc. raised its position in Bio-Techne by 1,118.3% in the second quarter. Assetmark Inc. now owns 1,401 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 1,286 shares during the last quarter. Atria Investments Inc raised its position in Bio-Techne by 31.1% in the second quarter. Atria Investments Inc now owns 7,484 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 1,774 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Bio-Techne by 134.6% during the second quarter. First Horizon Advisors Inc. now owns 868 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 498 shares in the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TECH has been the subject of several recent research reports. Stifel Nicolaus set a $65.00 price objective on Bio-Techne and gave the company a “hold” rating in a research note on Thursday, February 5th. Evercore lifted their target price on shares of Bio-Techne from $62.00 to $68.00 and gave the stock an “in-line” rating in a research report on Thursday, February 5th. Wells Fargo & Company boosted their target price on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Weiss Ratings upgraded shares of Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Finally, Robert W. Baird set a $70.00 price target on shares of Bio-Techne in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Bio-Techne presently has an average rating of “Moderate Buy” and an average target price of $72.77.

Bio-Techne Stock Performance

Shares of TECH stock opened at $52.82 on Wednesday. The firm has a 50 day moving average of $62.66 and a 200-day moving average of $60.04. The company has a market cap of $8.26 billion, a price-to-earnings ratio of 103.57, a price-to-earnings-growth ratio of 3.64 and a beta of 1.48. The company has a quick ratio of 3.08, a current ratio of 4.54 and a debt-to-equity ratio of 0.13. Bio-Techne Corp has a 52 week low of $46.01 and a 52 week high of $72.16.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03. The company had revenue of $295.88 million for the quarter, compared to the consensus estimate of $290.20 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. Bio-Techne’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.42 EPS. On average, equities analysts forecast that Bio-Techne Corp will post 1.67 earnings per share for the current year.

Bio-Techne Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Stockholders of record on Monday, February 16th were issued a dividend of $0.08 per share. The ex-dividend date was Friday, February 13th. This represents a $0.32 annualized dividend and a dividend yield of 0.6%. Bio-Techne’s dividend payout ratio is currently 62.75%.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.